204 related articles for article (PubMed ID: 26988703)
1. Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.
Chang YH; Li WH; Chang Y; Peng CW; Cheng CH; Chang WP; Chuang CM
BMC Cancer; 2016 Mar; 16():235. PubMed ID: 26988703
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC
Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
[TBL] [Abstract][Full Text] [Related]
3. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
4. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a Simple and Safe Tumor Drilling Technique to Potentiate the Effect of Intraperitoneal Chemotherapy in the Treatment of Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancer: A Matched Retrospective Cohort Study.
Chao WT; Chien CH; Lai CR; Wu HJ; Chuang CM
Cancer Control; 2019; 26(1):1073274819863778. PubMed ID: 31343898
[TBL] [Abstract][Full Text] [Related]
6. Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study.
Lu CH; Chang YH; Lee WH; Chang Y; Peng CW; Chuang CM;
Chemotherapy; 2016; 61(5):240-8. PubMed ID: 26930357
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
[TBL] [Abstract][Full Text] [Related]
8. Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
Miller EM; Tymon-Rosario J; Xie X; Xue X; Gressel GM; Miller DT; Kuo DY; Nevadunsky NS
Gynecol Oncol; 2017 Oct; 147(1):36-40. PubMed ID: 28751119
[TBL] [Abstract][Full Text] [Related]
9. Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
Chang YH; Lu CH; Yen MS; Lee WH; Chang Y; Chang WP; Chuang CM
Chin J Cancer; 2016 May; 35():45. PubMed ID: 27160669
[TBL] [Abstract][Full Text] [Related]
10. Update on the management and the role of intraperitoneal chemotherapy for ovarian cancer.
Teo MC
Curr Opin Obstet Gynecol; 2014 Feb; 26(1):3-8. PubMed ID: 24247932
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
12. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
Jaaback K; Johnson N
Cochrane Database Syst Rev; 2006 Jan; (1):CD005340. PubMed ID: 16437527
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Duska LR; Java JJ; Cohn DE; Burger RA
Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
[TBL] [Abstract][Full Text] [Related]
16. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
17. [Residual Disease Status after Primary Cytoreductive Surgery in Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Carcinoma and Long-Term Progression-Free Survival].
Otsuka I; Matsuura T
Gan To Kagaku Ryoho; 2016 Dec; 43(13):2547-2551. PubMed ID: 28028263
[TBL] [Abstract][Full Text] [Related]
18. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
[TBL] [Abstract][Full Text] [Related]
19. Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
Gao B; Lindemann K; Anderson L; Fereday S; Hung J; Alsop K; Tothill RW; Gebski V; Kennedy C; Balleine RL; ; Harnett PR; Bowtell DD; DeFazio A
Gynecol Oncol; 2016 Sep; 142(3):458-64. PubMed ID: 27444035
[TBL] [Abstract][Full Text] [Related]
20. Preclinical activity of melflufen (J1) in ovarian cancer.
Carlier C; Strese S; Viktorsson K; Velander E; Nygren P; Uustalu M; Juntti T; Lewensohn R; Larsson R; Spira J; De Vlieghere E; Ceelen WP; Gullbo J
Oncotarget; 2016 Sep; 7(37):59322-59335. PubMed ID: 27528037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]